Understanding how the tumor environment affects lung cancer treatment resistance
Official title: The Role of the Tumor Microenvironment in Resistance to Oncogenic KRAS Inhibition in Lung Cancer
Funded at University of Michigan at Ann Arbor · NIH-11003365 · Data updated 2026-11-12
This study is looking at how the area around lung tumors affects the way they respond to treatments, especially for patients with a specific type of lung cancer that has a KRAS mutation, to help find better ways to overcome treatment resistance.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Michigan at Ann Arbor NIH-funded |
| Lab location | 1 site (Ann Arbor, United States) |
| Project start | December 21, 2023 |
| Project end | November 30, 2025 |
| Funding year | 2025 |
| Award (this year) | $182,325 |
| NIH project number | 5R21CA286372-02 |
| Project ID | NIH-11003365 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with non-small cell lung cancer harboring KRAS mutations, especially those who have not smoked.
✕Less likely to help
Patients with lung cancer that does not involve KRAS mutations or those with other types of cancer may not benefit from this research.
What this research studies
This research investigates the role of the tumor microenvironment in lung cancer, particularly focusing on how it contributes to resistance against treatments targeting the KRAS oncogene. By utilizing advanced techniques like single-cell RNA sequencing, the study aims to analyze changes in the tumor environment during treatment and recurrence. The goal is to identify mechanisms of resistance that could inform future therapies, especially for patients with non-small cell lung cancer who have specific KRAS mutations. This research could lead to improved treatment strategies that enhance the effectiveness of existing therapies.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatment options for lung cancer patients, particularly those with KRAS mutations.
How similar studies have gone: Previous research has shown promising results in targeting KRAS mutations, indicating that this approach has potential for success.
Where this research is happening
-
University of Michigan at Ann Arbor
Ann Arbor, United States Active
Researchers
- Principal investigator: Galban, Stefanie — University of Michigan at Ann Arbor
- Study coordinator: Galban, Stefanie
Related research
Other NIH-funded projects on the same topics.
-
Blood-based markers to identify lung cancer risk in never-smokers
A researchers team at NYU School of Medicine is testing blood tests that might flag higher lung cancer risk in people who have never smoked, helping decide who might need screening.
-
Integrative Analysis of Lung Cancer Risk and Its Causes
A large, multi-part study at the University of New Mexico is exploring why lung cancer happens and how to better prevent and detect it.
-
Integrative Analysis of Lung Cancer Risk and Causes
A large NIH project is exploring how tobacco use, behavior, biology, and screening practices influence lung cancer risk and outcomes to help prevent and detect it earlier.
-
Digital health strategies to expand lung cancer screening in safety-net clinics
A funded project aims to help low-resource clinics increase the use of lung cancer screening for patients who smoke or are at risk.
-
Proteomics-guided matching of lung cancer tumors to preclinical models
This grant aims to improve how we match a patient’s lung cancer tumor to the right preclinical models using protein data.
-
Optimizing lung cancer care with smart tools for prevention, early detection, treatment, and survivorship
A U01 grant using AI and biomarkers to improve lung cancer prevention, screening, treatment, and survivorship care for people at risk or living with lung cancer.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.